Topsalycin in the treatment of prostate cancer: an update

Some 3 years ago we first commented on a Phase II trial of a drug now called topsalycin (but then known as PRX302) in the treatment of low- to intermediate-risk, localized prostate cancer. … READ MORE …

Computer modeling, genomics, and prostate cancer prognosis

A newly published paper on the development of prostate cancer in patients of ≤ 55 years of age claims to have shown that

Using a newly-developed computer model, it is now possible to predict the course of the disease in individual patients. … READ MORE …

And now, at 29 years of follow-up …

In this week’s issue of the New England Journal of Medicine, Bill-Axelson et al. offer data from a sixth update to the outcomes from the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) trial of radical prostatectomy vs. watchful waiting … READ MORE …

MFS as an endpoint in clinical trials

Earlier this year, two drugs (apalutamide/Erleada and enzalutamide/Xtandi) were each approved for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC) based on the use of metastasis-free survival (MFS) as the study endpoint in clinical trials. … READ MORE …

Pembrolizumab in treatment of advanced prostate cancer

We finally have some published data — albeit not a lot — on the use of one of the PD-1 inhibitors (pembrolizumab, also known as Keytruda) in the treatment of late-stage prostate cancer. … READ MORE …

When it comes to post-surgical exercise …

Perhaps understandably, the average prostate cancer patient seems to be less exercise willing than he thinks (and reports that) he is — but it’s not all bad news! … READ MORE …

Is IBD a risk factor for prostate cancer — and if so, how serious?

A newly published report in European Urology has suggested that men who have inflammatory bowel disease (IBD) — either Crohn’s disease or ulcerative colitis — are at a significantly increased risk for prostate cancer over time. … READ MORE …